EADV 2020 AC5 IN THE MANAGEMENT OF MILD ANDROGENETIC ALOPECIA : RESULTS FROM A LARGE INTERNATIONAL OBSERVATIONAL STUDY

INTRODUCTION

Androgenetic alopecia (AGA) is a chronic scalp condition, representing the primary cause of hair loss in both women and men.1

AGA manifests in different clinical patterns among women and men. In women, AGA or female pattern of hair loss (FPHL) results in a decreased hair density and thickness predominantly in the frontal area with a sparse pattern.1-3 Male pattern of hair loss (MPHL) presents predominantly in the temporal areas and the vertex more regularly than FPHL.4

Alopecia causes emotional distress, impact the individual’s quality of life and can also be the first symptom of an underlying systemic disease.5, 6

AC5 contains 2.4-Diamino-Pyrimidine-N-Oxyde(DPNO, Aminexil), Arginine, 6-O glucose linoleate

(SP94), Piroctone olamine and Vichy volcanic mineralizing water (VVMW) as active ingredients; which have proven their benefits in hair loss or inflammation shown the benefit in hair loss orskin inflammation.7-10 Figure 1 and Figure 2 show the benefit of DPNO alone on hair growth as published by Loussouarn.9